Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 14.38B P/E 16.34 EPS this Y - Ern Qtrly Grth 32.00%
Income 1.05B Forward P/E - EPS next Y - 50D Avg Chg -12.00%
Sales 5.78B PEG - EPS past 5Y - 200D Avg Chg -27.00%
Dividend 2.00% Price/Book 1.62 EPS next 5Y - 52W High Chg -38.00%
Recommedations - Quick Ratio 0.87 Shares Outstanding 189.17M 52W Low Chg -
Insider Own 37.95% ROA 5.97% Shares Float 120.84M Beta 0.41
Inst Own 40.18% ROE 13.48% Shares Shorted/Prior -/- Price 76.00
Gross Margin 75.11% Profit Margin 18.31% Avg. Volume 282 Target Price -
Oper. Margin 22.75% Earnings Date - Volume 1,045 Change 0.00%
UCB S.A. News
05/23/22 UCB Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to be Presented at EULAR 2022
05/23/22 First Presentations of Phase 3 Data for Bimekizumab Across the Full Spectrum of Axial Spondyloarthritis to be Shared at EULAR 2022
05/10/22 UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis
05/02/22 JAMA Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of FINTEPLA® (fenfluramine) Oral Solution in Lennox-Gastaut Syndrome (LGS)
04/25/22 Here's Why Momentum in UCB SA (UCBJF) Should Keep going
04/01/22 UCB Showcases Strength of Broad Neurology Portfolio at 74th American Academy of Neurology (AAN) Annual Meeting
03/31/22 What Makes UCB SA (UCBJF) a Good Fit for "Trend Investing"
03/28/22 UCB's Rare Childhood Epilepsy Drug Scores FDA Approval
03/28/22 UPDATE 2-U.S. FDA approves UCB's drug for rare childhood epilepsy
03/28/22 FINTEPLA® (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)
03/26/22 New Long-Term Complete Skin Clearance Data for Bimekizumab in Moderate to Severe Plaque Psoriasis Presented at the 2022 AAD Annual Meeting
03/25/22 UCB SA/NV - CONVENING NOTICE TO THE GENERAL MEETING OF SHAREHOLDERS 2022
02/08/22 Biogen (BIIB) Inks Agreement to Add New Biosimilar Candidate
02/04/22 UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results
01/21/22 Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study
01/19/22 ZGNX Stock: The $1.9B UCB Deal That Has Zogenix Shares Zooming Higher Today
01/19/22 Zogenix Surges After UCB's $1.9B Acquisition Offer
01/19/22 UCB to acquire Zogenix
01/18/22 Positive Top-Line Results for bimekizumab in Phase 3 Non-Radiographic Axial Spondyloarthritis Study

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.